FDA PMA FDA Class 3 Approved 🇺🇸 United States

Percutaneous Cardiac Ablation Catheter For Treatment Of Atrial Fibrillation With Irreversible Electroporation

PMA: P250022 · Supplement: S001 · Decision Mar 23, 2026
Classifications
1
FEI Numbers
0
Registration Numbers
0

Basic Information

Device Name
Percutaneous Cardiac Ablation Catheter For Treatment Of Atrial Fibrillation With Irreversible Electroporation
Trade Name
Volt PFA Catheter Sensor Enabled™
PMA Number
P250022
Supplement Number
S001
Device Class
FDA Class 3
Product Code
QZI
Generic Name
Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation
Medical Specialty
Unknown
Advisory Committee
Cardiovascular
Decision
Approved
Decision Code
APPR
Decision Date
March 23, 2026
Date Received
December 23, 2025
Supplement Type
Normal 180 Day Track
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N

Advisory Committee Statement

approval for minor design modifications, addition of Alajuela, Costa Rica as a manufacturing site, addition of Minnetonka, Minnesota as a basket subassembly manufacturing site, and addition of two Ethylene Oxide sterilization sites. Additionally, you requested approval for a Pre-Determined Change Control Plan (PCCP) that establishes updates to component suppliers for second source components for the balloon, splines, and center lumen of the catheter, provided they do not impact the specifications, the established methods for its sourcing, handling, and testing, or the qualification standards for supplier facilities and personnel for the devices under the above PMA.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
QZI Percutaneous Cardiac Ablation Catheter For Treatment Of Atrial Fibrillation With Irreversible Electroporation